...
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Latest advances in biomarker discovery and development.
【24h】

Latest advances in biomarker discovery and development.

机译:生物标志物发现和开发的最新进展。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Oxford Global's 7th Annual Biomarkers Congress, held February 21-22, 2012, in Manchester (UK), gathered together approximately 300 delegates and speakers with a specific interest in biomarkers and their application in the field of drug discovery and development, as well as their enabling technologies. The audience and participants came from diverse and mixed backgrounds, from academicians and industry business professionals to representatives of solutions providers and CROs offering services in the field of biomarker assay development and sample analysis. Focus was broad, including all types of biomarkers and their application, i.e., prognostic and diagnostic markers, predictive markers, patient selection strategies in drug development, point-of-care solutions, pharmacodynamic and target engagement biomarkers as well as safety-related approaches. There were presentations spanning the entire range of biomarker development, from discovery to clinical qualification and analytical validation of a specific marker or a markers panel. A wide range of therapeutic areas were also covered; however, the fields of oncology and inflammatory diseases were more prominent, since they currently provide best case studies for biomarker discovery and clinical utility.
机译:牛津全球第七届年度生物标志物大会于2012年2月21日至22日在英国曼彻斯特举行,聚集了约300名对生物标志物及其在药物发现和开发领域的应用以及他们的应用特别感兴趣的代表和演讲者支持技术。观众和参与者来自不同和混杂的背景,从院士和行业业务专业人员到解决方案提供商和提供生物标志物测定开发和样品分析领域服务的CRO的代表。重点是广泛的,包括所有类型的生物标志物及其应用,即预后和诊断标志物,预测性标志物,药物开发中的患者选择策略,即时护理解决方案,药效学和靶标参与性生物标志物以及与安全相关的方法。演讲涉及生物标志物开发的整个范围,从发现到临床鉴定以及对特定标志物或标志物组的分析验证。还涵盖了广泛的治疗领域;然而,肿瘤学和炎性疾病领域更为突出,因为它们目前为生物标志物的发现和临床应用提供了最佳的案例研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号